![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sinovac Completes Acquisition of Additional 20.56 Percent of Beijing Subsidiary
Sinovac Completes Acquisition of Additional 20.56 Percent of Beijing Subsidiary
Sinovac Biotech Ltd. has announced that as of Feb. 4 it has completed the acquisition of an additional 20.56 percent of its Beijing-based operating subsidiary, Sinovac Biotech Co. Ltd. (Sinovac (Beijing)) for approximately US$3,310,000. Sinovac's intention to make this purchase was previously announced on Dec. 10, 2004. Sinovac's holdings now include nearly 72 percent of Sinovac (Beijing) and 100 percent of the Tangshan Yian R&D and production facility. The Tangshan Yian facility was acquired by Sinovac in February 2004 and is now a 100-percent-owned subsidiary. China Bioway Biotech Group (China Bioway), a subsidiary of Beijing University, owns the remaining 28 percent of Sinovac (Beijing).
Yahoo News (http://biz.yahoo.com/bw/050209/95395_1.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct